An allogeneic dendritic cell vaccine for patients who have residual cancer after previous successful treatments with chemotherapy has shown positive survival data, according to the developer Mendus AB. The treatment, DCP-001, is being evaluated in a Phase 2 trial as a maintenance therapy in acute myeloid leukaemia (AML) for patients with measurable residual disease. Fresh data from the trial, ADVANCE II, was reported at the American Society of Hematology Annual Meeting on 12 December.
